Saı̈d M. Sebti

20.7k citations

250 papers · 16.7k indexed · 1 hit paper · h-index 73

Oncology top 0.2%
- Cancer-related Molecular Pathways 75
- Cytokine Signaling Pathways and Interactions 30
- Peptidase Inhibition and Analysis 18
Molecular Biology top 0.2%
- Protein Kinase Regulation and GTPase Signaling 59
- PI3K/AKT/mTOR signaling in cancer 45
- Ubiquitin and proteasome pathways 41
- Melanoma and MAPK Pathways 22
- Cell death mechanisms and regulation 18
Toxicology top 0.2%
Cancer Research top 0.5%
Immunology top 1%

Co-authors: Andrew D. Hamilton Jiazhi Sun Yimin Qian Michelle A. Blaskovich Richard Jove James Turkson Nicholas J. Lawrence Norbert Berndt
Cited by: Oncology Molecular Biology Toxicology
Journals: Journal of Biological Chemistry (20 papers)Cancer Research (20 papers)Oncogene (16 papers)
Partner nations: United States China France

In The Last Decade

Saı̈d M. Sebti

248 papers receiving 16.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Saı̈d M. Sebti

Since Specialization

Citations

This map shows the geographic impact of Saı̈d M. Sebti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saı̈d M. Sebti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saı̈d M. Sebti more than expected).

Fields of papers citing papers by Saı̈d M. Sebti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saı̈d M. Sebti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saı̈d M. Sebti. The network helps show where Saı̈d M. Sebti may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Saı̈d M. Sebti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Saı̈d M. Sebti Line = papers co-authored together Saı̈d M. Sebti links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I Chemistry - A European Journal ·Νικόλαος Σακελλαρίδης,俊裕矢内,Сарапулов Сергей Николаевич,(unknown),Yoshihisa Inoue,Shiro Iwanaka,Takeyuki Suzuki,Saı̈d M. Sebti,Junko Ohkanda	2025	1
2	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer Clinical Cancer Research ·Aslamuzzaman Kazi,Liwei Chen,Shengyan Xiang,慶雄沖,Hua Yang,Francisca Beato,Bin Fang,Terence M. Williams,Kazim Husain,Patrick W. Underwood,Jason B. Fleming,Mokenge P. Malafa,Eric A. Welsh,John M. Koomen,José G. Treviño,Saı̈d M. Sebti	2021	25
3	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results Clinical Cancer Research ·Joseph Pidala,Kelly Walton,Hany Elmariah,Jongphil Kim,Asmita Mishra,Nelli Bejanyan,Taiga Nishihori,Farhad Khimani,Lia Perez,Rawan Faramand,Marco L. Davila,Michael L. Nieder,Elizabeth M. Sagatys,Shernan G. Holtan,Nicholas J. Lawrence,Harshani R. Lawrence,Bruce R. Blazar,Claudio Anasetti,Saı̈d M. Sebti,Brian C. Betts	2021	15
4	CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function Cancer Immunology Research ·Justin C. Boucher,Gongbo Li,Hiroshi Kotani,Maria L. Cabral,Dylan Morrissey,Sae Bom Lee,Kristen Spitler,Ramachandra Menon,Thanchanok Wadmuang,Bishwas Shrestha,Bin Yu,Aslamuzzaman Kazi,Xuefeng Wang,Saı̈d M. Sebti,Marco L. Davila	2020	48
5	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors Clinical Cancer Research ·Aslamuzzaman Kazi,Shengyan Xiang,Hua Yang,Liwei Chen,Perry Kennedy,Muhammad Ayaz,Steven Fletcher,Christopher T. Cummings,Harshani R. Lawrence,Francisca Beato,Ya’an Kang,Michael P. Kim,Andrea E. Delitto,Patrick W. Underwood,Jason B. Fleming,José G. Treviño,Andrew D. Hamilton,Saı̈d M. Sebti	2019	53
6	A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation Cancer Research ·Xiaolei Zhang,Ying Sun,Roberta Pireddu,Hua Yang,Augustin Sodjinou,Harshani R. Lawrence,Wayne C. Guida,Nicholas J. Lawrence,Saı̈d M. Sebti	2013	122
7	Selective Disruption of Rb–Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity Molecular Cancer Therapeutics ·José G. Treviño,Monika Verma,Sandeep Singh,Smitha Pillai,Dongyu Zhang,سحر قاضی زاده,Saı̈d M. Sebti,Nicholas J. Lawrence,Barbara A. Centeno,Srikumar Chellappan	2013	6
8	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity Cancer Research ·Fengdong Cheng,Hongwei Wang,Pedro Horna,Zi Wang,Bijal Shah,Eva Sahakian,Karrune Woan,Alejandro Villagra,Javier Pinilla‐Ibarz,Saı̈d M. Sebti,Mitchell R. Smith,Jianguo Tao,Eduardo M. Sotomayor	2012	15
9	RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer Cancer Research ·Vittorio Caporali,Laser Confirence Exposition,Roberta Pireddu,Ying Sun,Nan Sun,Mathew P. Martin,E. Schönbrunn,Nicholas J. Lawrence,Saı̈d M. Sebti	2012	123
10	Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice Clinical Cancer Research ·Maria E. Balasis,Laser Confirence Exposition,Y. Ann Chen,William J. Fulp,Domenico Coppola,Andrew D. Hamilton,Jin Q. Cheng,Saı̈d M. Sebti	2011	55
11	Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins Molecular Cancer Therapeutics ·Jun Wei,Shinichi Kitada,Michele F. Rega,Aras Emdadi,Hongbin Yuan,Jason Cellitti,John L. Stebbins,Dayong Zhai,Jiazhi Sun,Li Yang,Russell Dahl,Ziming Zhang,Bainan Wu,Si Wang,Reynaldo Fabrizzio Miranda Fidhel,Nicholas J. Lawrence,Saı̈d M. Sebti,John C. Reed,Maurizio Pellecchia	2009	51
12	A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice Cancer Research ·Rebecca Kinkade,Piyali Dasgupta,Adam Carie,سحر قاضی زاده,Melanie A. Carless,Smitha Pillai,Nicholas J. Lawrence,Saı̈d M. Sebti,Srikumar Chellappan	2008	45
13	Delta-tocotrienol is the most bioactive natural tocotrienol in the prevention of pancreatic cancer transformation Cancer Research ·Kazim Husain,R François,昭次富田,Saı̈d M. Sebti,Mokenge P. Malafa	2008	2
14	Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide Journal of Clinical Oncology ·Joseph A. Sparano,Stacy L. Moulder,Aslamuzzaman Kazi,Linda T. Vahdat,Tianhong Li,Christine Pellegrino,P.N. Munster,Mokenge P. Malafa,David Lee,Sanda Rajhvajn,Una Hopkins,Dawn L. Hershman,James R. Wright,Saı̈d M. Sebti	2006	54
15	Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x _L Journal of the American Chemical Society ·Hang Yin,Gaudreault,Ghilherme Borges,Olaf Kutzki,Hyung Soon Park,Brendan P. Orner,Justin T. Ernst,Hong‐Gang Wang,Saı̈d M. Sebti,Andrew D. Hamilton	2005	166
16	A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells Journal of Biological Chemistry ·James Turkson,Shumin Zhang,Linda Mora,Katarzyna. Siedlaczek,Saı̈d M. Sebti,Richard Jove	2005	135
17	Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt Cancer Research ·Lin Yang,Han C. Dan,Mei Sun,Qiyuan Liu,CHENILY ANDRADE RIBEIRO,Richard I. Feldman,Andrew D. Hamilton,Mark A. Polokoff,Santo V. Nicosia,Meenhard Herlyn,Saı̈d M. Sebti,Jin Q. Cheng	2004	360
18	Blocked Pathways: FTIs Shut Down Oncogene Signals The Oncologist ·Saı̈d M. Sebti	2003	19
19	Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein Molecular and Cellular Biology ·James Turkson,Tammy Bowman,Jalila Adnane,Yi Zhang,Julie Y. Djeu,Madhavi Sekharam,David A. Frank,Lawrence B. Holzman,Jie Wu,Saı̈d M. Sebti,Richard Jove	1999	226
20	Farnesyltransferase inhibitors: Anti-Ras drugs for cancer treatment Anti-Cancer Drugs ·Channing J. Der,Adrienne D. Cox,Saı̈d M. Sebti,Andrew D. Hamilton	1996	2

About Saı̈d M. Sebti

Saı̈d M. Sebti is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 250 papers that have together received 16.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (75 papers), Protein Kinase Regulation and GTPase Signaling (59 papers), PI3K/AKT/mTOR signaling in cancer (45 papers), Ubiquitin and proteasome pathways (41 papers), Cytokine Signaling Pathways and Interactions (30 papers), Melanoma and MAPK Pathways (22 papers), Cell death mechanisms and regulation (18 papers) and Peptidase Inhibition and Analysis (18 papers). The work is most often cited by research in Oncology (6.7k citations), Molecular Biology (11.0k citations) and Toxicology (467 citations). Saı̈d M. Sebti has collaborated with scholars based in United States, China and France. Frequent co-authors include Andrew D. Hamilton, Jiazhi Sun, Yimin Qian, Michelle A. Blaskovich, Richard Jove, James Turkson, Nicholas J. Lawrence, Norbert Berndt, Harshani R. Lawrence and Domenico Coppola. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research, Oncogene, Blood and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact